Patty Keating breaks down the role of advocacy groups, long-term monitoring, and how to better understand the emotional ...

3,4 It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism. Hypoparathyroidism is a rare, complex ...

Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma. Yorvipath (palopegteriparatide) – previously known as TransCon ...

SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two ...

Medically reviewed by Isabel Casimiro, MD, PhD Hypoparathyroidism is a rare condition characterized by the diminished ...

"Until now, the only treatment option for adults with chronic hypoparathyroidism has been conventional therapy with calcium and active vitamin D supplementation to keep blood calcium levels normal ...

3,4 It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism. Leading Australian Endocrinologist and Head ...